ABVX:EPA
Abivax SA
76,45 €
arrow_upward
+1,26%(+0,95) 1D
18-ноя., 15:55:09 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
75,50 €
High
76,55 €
Low
75,10 €
Mkt. cap
6,69 млд
Avg. vol.
109,70 миң
Volume
22,09 миң
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
Open
75,50 €
High
76,55 €
Low
75,10 €
Mkt. cap
6,69 млд
Avg. vol.
109,70 миң
Volume
22,09 миң
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
News stories
From web sources and news partners
San Luis Obispo Tribune
·
18 мүнөт мурун
S&P 500, Nasdaq open higher as Nvidia forecast eases AI jitters
Coinpaper
·
7 мүнөт мурун
Dow Jones: Wall Street Eyes Rebound as Morgan Stanley Targets S&P 500 at 8,700
Yahoo Finance
·
54 мүнөт мурун
Investors Love the S&P 500 Index. Here’s Why I Don’t.
ChartMill
·
1 саат мурун
S&P 500 Premarket Movers on Nov. 18
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013-ж., 4-дек.
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteabivax.com